secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001193125-24-071353
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio stockholders approve 1:7 reverse split, name change to LENZ; effective March 21, trading as LENZ March 22
--------------------------------------------------------------------------------

- Stockholders approved 1-for-7 reverse stock split and name change to 'LENZ Therapeutics, Inc.' at March 14 special meeting.
- Reverse split and name change effective 4:01 p.m. ET March 21, 2024; no fractional shares, cash paid in lieu.
- Common stock trades on split-adjusted basis under ticker 'LENZ' from March 22, 2024; new CUSIP 52635N103.
- Proportional adjustments made to outstanding equity awards and shares reserved under stock plans.
- Actions taken in connection with pending merger with LENZ Therapeutics; merger closing expected thereafter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000119312524071353/0001193125-24-071353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000119312524071353/d780027d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-071353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer